real-time news and commentary for investors
Thursday, Aug 22
Regado Biosciences has a solid market debut despite Nasdaq's problems
- Cardiovascular treatment company Regado Biosciences (RGDO) finish the day solidly higher on its market debut after earlier pricing its 10.7 million share IPO at $4.
- The offering differed significantly from its original plans. In early May the company disclosed plans to sell around 5M shares at $14 to $16 each. That was later revised to 8.4 shares priced at $5.
- Trading has been caught up in the afternoon-long trading halt for the Nasdaq exchange, with just over 223,000 shares changing hands through mid-day before trading was suspended.
- The shares traded as high as $5.39 each soon after the stock opened, seldom trading much below $4.80 a share.